21 CFR Part 11

For software sold into pharma, biotech, and clinical labs, Part 11 compliance is a gate: systems must be validated and must maintain tamper-evident audit trails and controlled signatures. It shapes how lab informatics, LIMS, and quality systems are built and implemented far more than feature lists do.

In practice

In day-to-day operations within the life sciences industry, 21 CFR Part 11 significantly impacts quality assurance teams, IT departments, and regulatory compliance officers. These professionals must ensure that electronic systems for data capture and signatures are compliant, which drives decisions around software selection, validation protocols, and data integrity measures. Compliance with this regulation is critical commercially, as it helps prevent costly penalties and product recalls while ensuring data is reliable for regulatory submissions and audits.

Where 21 CFR Part 11 shows up on MarketScale

FDA QMSR ties supplier contracts to inspection prephealthcare FDA-authorized digital medical devices have grown substantially over two decades, but regulatory databases still can't track themhealthcare Pharma Manufacturing: Meeting Annex I with Precision Machining for Safer Sterile Drug Productionhealthcare What Updated Annex 1 Regulations Mean for Sterile Manufacturing Companies in 2023sciences IQVIA's new white paper maps how digital health technologies can reshape CNS clinical trial endpointshealthcare Setting the Benchmark: Adapting to Evolving Life Science Regulations with Benchmark Productsbusiness services FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide deckshealthcare What Challenges Are Manufacturers Facing Under Annex 1?engineering and construction

Try the MarketScale platform free. No demo required.